Cargando…
Hormone Replacement Therapy Appears to Be Safe After Prophylactic Adnexectomy in Premenopausal BRCA1/BRCA2 Mutation Carriers. Reaction to the 'Letter to readers' in Hereditary Cancer in Clinical Practice, 2005, 3 (2)
In writing the letter to readers of our journal three months ago I was asking about opinions concerning the use of hormone replacement therapy (HRT) in BRCA1/2 carriers after prophylactic adnexectomy, because at that time it was practically impossible to present evidence-based recommendations. Actua...
Autor principal: | Lubiński, Jan |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837296/ http://dx.doi.org/10.1186/1897-4287-3-3-87 |
Ejemplares similares
-
The Effect of Prophylactic Adnexectomy on the Quality of Life and Psychosocial Functioning of Women with the BRCA1/BRCA2 Mutations
por: Stanisz, Marta, et al.
Publicado: (2019) -
The expression of BRCA1, P53, KAI1, and Nm23 in ovaries of BRCA1 mutation carriers after prophylactic adnexectomy
por: Markowska, J., et al.
Publicado: (2013) -
Clinical outcome for BRCA1 and BRCA2 mutation carriers after contralateral prophylactic mastectomy
por: Schmidt, MK, et al.
Publicado: (2005) -
Hormone Replacement Therapy after Prophylactic Adnexectomy
por: This, Pascale, et al.
Publicado: (2005) -
The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
por: Iqbal, J, et al.
Publicado: (2012)